Clinical trials: Disorder of Vein
Venous Ulcer
A Trial to Assess the Safety and Activity of Nexagon® for the Treatment of Venous Leg Ulcers (The NOVEL Study)
Venous leg ulcers are a common, costly and debilitating condition, with few effective treatments. Compression bandaging helps healing, but more than four out of every ten leg ulcers remain unhealed after three months.
- Trial name
- NCT00820196
- Testing
- Nexagon®, Nexagon® vehicle
- Where
- 10 sites in United States, New Zealand
- Volunteers
- 98 people
- Sponsor
- OcuNexus Therapeutics, Inc.
Venous Insufficiency
Open Label Safety Investigation of Solutio™ Tumescent Catheter
The goal of this clinical investigation is to evaluate safety of the Solutio™ catheter when administering tumescent anesthesia before treatment with endothermal ablation in adults above the age of 18, who suffer from unilateral…
- Trial name
- NCT07823088
- Testing
- Administration of local anesthesia
- Where
- 2 sites in Sweden
- Volunteers
- 30 people
- Sponsor
- MedVasc AB
Chronic Wound, Venous Leg Ulcer
Clinical Study to Compare 3 Multi-Layered Foam Dressings for the Management of Chronic Wounds
A prospective, randomized, controlled clinical trial (RCT) using a cross-over (repeated measures) design to evaluate safety and efficacy of three foam wound dressings in the local management of chronic wounds.
- Conditions
- Chronic Wound, Venous Leg Ulcer, Diabetic Foot Ulcer
- Trial name
- NCT03662997
- Testing
- Bordered Five-Layer Foam Dressing, Hydropolymer Foam Dressing, Hydrocellular Multi-Layer Foam Dressing
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Molnlycke Health Care AB
Diabetic Foot Ulcers (DFU), Venous Stasis Ulcers (VSU)
OASIS Wound Matrix (Oasis) Mechanism of Action
OASIS Wound Matrix (Oasis) will be applied to wounds, with sequential biopsy of healing wounds to explore the mechanism of action.
- Trial name
- NCT00570141
- Testing
- OASIS Wound Matrix
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Healthpoint
Wounds and Injuries, Venous Leg Ulcer
DURAFIBER Ag Post-Market Clinical Follow-Up
The aim of the study is to evaluate the performance of DURAFIBER Ag and to assess how many bacteria are present in infected wounds over an 8 week period.
- Conditions
- Wounds and Injuries, Venous Leg Ulcer, Infection
- Trial name
- NCT03277131
- Testing
- DURAFIBER Ag
- Where
- 7 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Smith & Nephew, Inc.
Lymphedema, Lymphedema of Leg
A Clinical Study to Evaluate the Effectiveness of a Novel Portable Non-Pneumatic Active Compression Device vs. an Advanced Pneumatic Compression Device for Treating Lower Extremity Lymphedema
To evaluate the Koya wearable device - a Novel Portable Non-Pneumatic Active Compression Device (NPCD) in contrast to an advanced pneumatic compression device (APCD)
- Conditions
- Lymphedema, Lymphedema of Leg, Chronic Venous Insufficiency, Venous Insufficiency
- Trial name
- TEAYS (NCT05507346)
- Testing
- Cross over Device (PCD or Dayspring - alternate to first group)
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Koya Medical, Inc.
Lymphedema, Chronic Venous Insufficiency
A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of Insight® Pro Device for Evaluating Lymphatic and Venous Disorders (VOLGA)
To demonstrate that the Insight Pro Device is safe and effective for use in detecting lymphatic and venous disorders.
- Conditions
- Lymphedema, Chronic Venous Insufficiency, Edema, Venous Insufficiency of Leg
- Trial name
- VOLGA (NCT05628688)
- Testing
- Insight Pro Device for Diagnosis
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Koya Medical, Inc.
Venous Leg Ulcer, Venous Leg
Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot and Venous Leg Ulcers.
Title A Multicenter, Prospective, Randomized Controlled Modified Multi-Platform (Matriarch) Trial Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care versus Standard of Care alone in the…
- Conditions
- Venous Leg Ulcer, Venous Leg, Diabetic Foot, Diabetic Foot Ulcer
- Trial name
- NCT06826339
- Testing
- ACApatch™, caregraFT™, Standard of Care
- Where
- United States
- Volunteers
- 340 people
- Sponsor
- Tiger Biosciences, LLC.
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT)
Cancer Venous Thromboembolism (VTE)
The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of LMWH) compared with dalteparin for the prevention of the combined outcome of recurrent venous thromboembolism (VTE) or major…
- Conditions
- Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cancer
- Trial name
- NCT02073682
- Testing
- Edoxaban, Dalteparin, Low molecular weight heparin
- Where
- 9 sites in United States, Belgium and 4 more
- Volunteers
- 1,046 people
- Sponsor
- Daiichi Sankyo
Atrial Fibrillation
AtriCure Minimally Invasive Surgical Ablation for Atrial Fibrillation/RESTORE IIB
Feasibility study arm to evaluate the safety of adding the left atrial linear connecting lesions of the Cox-Maze lesion set to the current RESTORE SR II IDE study procedure of performing pulmonary vein isolation, selected left…
- Trial name
- RESTORE SR IIB (NCT00571779)
- Testing
- AtriCure Bipolar System
- Sponsor
- AtriCure, Inc.
Retinal Vein Occlusion
Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO)
This is a prospective, non-interventional, multi center post-authorization safety study that includes patients with a diagnosis of CRVO.
- Trial name
- JPMS-CRVO (NCT02040220)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Japan
- Volunteers
- 385 people
- Sponsor
- Bayer
Thromboembolism
A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)
This is a multi-center, prospective, international, randomized (1:1), open-label study with two parallel groups. This phase III study is planned to investigate the efficacy and safety of dabigatran etexilate versus dose-adjusted…
- Trial name
- NCT02913326
- Testing
- Dabigatran etexilate, Warfarin
- Where
- 36 sites in France, Germany and 7 more
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
End-Stage Renal Disease Requiring Haemodialysis
DisTal Arterio-Venous Fistula Feasibility
The goal of this clinical trial is to evaluate, in a clinical setting, the feasibility of vein enlargement at the site of the arteriovenous fistula created percutaneously, using the DisTal device ("DisTal AVF").
- Trial name
- DisTal (NCT07786025)
- Testing
- DisTal
- Where
- Dominican Republic
- Volunteers
- 100 people
- Sponsor
- Distal Inc.
Wounds, Other Ulcers Wounds and Skin Problems
Safety and Efficacy of Topical AR/101 Compared With Placebo, in Accelerating Granulation Tissue Formation of Hard-to-heal Wounds
This prospective, placebo-controlled, double blind, randomized study is designed to assess the healing effects of AR/101 on chronic Hard-to-Heal wound(s) of different etiologies including arterial ulcers, diabetic ulcers and…
- Trial name
- NCT02839226
- Testing
- AR/101
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Arava Bio Tech Ltd.
Venous Thromboembolism
An Observational Study on Incidence, Natural History and Treatment Patterns of Venous Thromboembolism in Taiwan
The research question addressed by this study is primarily on the clinical epidemiology of VTE in Taiwan. The study aims to estimate the incidence of VTE and describe natural history of VTE, including long term clinical outcomes…
- Trial name
- NCT03799016
- Where
- Taiwan
- Volunteers
- 104,215 people
- Sponsor
- Bayer
Venous Thromboembolism
Multicenter Registry for Effectiveness Analysis of ActiveCare+S.F.T® Mobile Compression Device for Thrombosis Prevention in Hip and Knee Arthroplasty
Venous thromboembolic events (VTE), either deep vein thromboses or pulmonary emboli, are important complications in patients undergoing knee or hip arthroplasty.
- Trial name
- ACOR (NCT01984190)
- Where
- 10 sites in United States
- Volunteers
- 411 people
- Sponsor
- Medical Compression Systems
Retinal Vein Occlusion
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion
Open-label, dose ascending safety, tolerability, and proof of concept study to evaluate the use of ANXV (human recombinant Annexin A5) in the treatment of subjects with recently diagnosed Retinal Vein Occlusion.
- Trial name
- NCT05532735
- Testing
- ANXV
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- Annexin Pharmaceuticals AB
Thromboembolism
Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)
The purpose of this study is to find the best possible (optimal) dose (effect versus adverse events) of YM150 to prevent the risk of blood clot formation after scheduled hip replacement surgery.
- Trial name
- NCT00353678
- Testing
- YM150
- Where
- 79 sites in Austria, Bosnia and Herzegovina and 15 more
- Volunteers
- 1,141 people
- Sponsor
- Astellas Pharma Inc
Thromboembolism, Arthroplasty, Replacement, Hip
Study to Evaluate the Safety and Efficacy of Pradaxar for the Prevention of Venous Thromboembolism in the Mexican Population Undergoing Elective Total Hip or Knee Replacement Surgery
Open, prospective, uncontrolled, observational cohort study.
- Trial name
- NCT00967447
- Where
- 28 sites in Mexico
- Volunteers
- 2 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism
Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer
The purpose of this study is to assess the efficacy and safety of Innohep® in preventing the recurrence of VTE in patients with active cancer who have had an acute VTE episode.
- Trial name
- NCT01130025
- Testing
- Warfarin, Innohep®
- Where
- Canada
- Volunteers
- 900 people
- Sponsor
- LEO Pharma